Group 1 - Dongcheng Pharmaceutical's stock increased by 5.01%, reaching 15.50 CNY per share, with a trading volume of 201 million CNY and a turnover rate of 1.78%, resulting in a total market capitalization of 12.781 billion CNY [1] - The company, established on December 31, 1998, and listed on May 25, 2012, specializes in the research, production, and sales of heparin sodium raw materials and chondroitin sulfate [1] - The revenue composition of Dongcheng Pharmaceutical includes 44.16% from raw materials, 36.38% from nuclear medicine products, 13.17% from formulations, and 6.30% from other sources [1] Group 2 - According to data, one fund under Industrial Bank holds Dongcheng Pharmaceutical as a significant investment, with 1.2349 million shares, accounting for 4.65% of the fund's net value, making it the sixth-largest holding [2] - The fund, named Industrial Medical Care A (011466), has a current scale of 261 million CNY and has achieved a year-to-date return of 22.76%, ranking 4158 out of 8154 in its category [2] - The fund has a one-year return of 14.98%, ranking 5070 out of 8046, and has experienced a cumulative loss of 20.27% since its inception [2]

10月30日，泽璟制药涨5.09%，截至发稿，报91.43元/股，成交2.79亿元，换手率1.18%，总市值242.02 亿元。 资料显示，苏州泽璟生物制药股份有限公司位于江苏省昆山市玉山镇晨丰路262号，成立日期2009年3月 18日，上市日期2020年1月23日，公司主营业务涉及化学新药及生物新药的研发、生产及销售。主营业 务收入构成为：药品99.97%，医药中间体及原辅料0.02%，资产租赁0.00%。 截至发稿，陈旭累计任职时间4年238天，现任基金资产总规模4.04亿元，任职期间最佳基金回 报-19.16%， 任职期间最差基金回报-21.01%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，兴业基金旗下1只基金重仓泽璟制药。兴业医疗保健A（011466）三季度持有股数14.3万股， 与上期相比持股数量不变，占基金净值比例为4%，位居第九大重仓股。根据测算，今日浮盈赚取约 63.34万元。 兴业医疗保健A（011466）成立日期2 ...

Core Insights - Tonghua Dongbao Pharmaceutical (300636.SZ) released its Q3 2025 report on October 25, 2025, indicating a total of 63.9184 million A-shares held by three institutional investors, accounting for 15.22% of the company's total share capital [1] - The institutional holding percentage decreased by 1.80 percentage points compared to the previous quarter [1] Institutional Investors - The three institutional investors include: - Fong Lung Industrial Co., Ltd. - Guotai Junaq Securities' special pension product from China Merchants Bank - Jiangxi Chinese Media Blue Ocean International Investment Co., Ltd. [1] - The total institutional holding ratio stands at 15.22% [1] Public Funds - A total of 58 public funds were not disclosed in the current period compared to the previous quarter, including: - Galaxy Medical Mixed A - Industrial Bank Healthcare A - Galaxy Kang Le Stock A - Fuanda Medical Innovation Mixed - Xiangcai Medical Health Mixed A [1]

Core Viewpoint - The stock of Zhejiang Sitaili Pharmaceutical Co., Ltd. experienced a 6.12% increase, reaching 12.65 CNY per share, with a total market capitalization of 5.546 billion CNY as of September 15 [1] Group 1: Company Overview - Zhejiang Sitaili Pharmaceutical Co., Ltd. was established on September 15, 1997, and went public on March 9, 2016 [1] - The company specializes in the production and sales of non-ionic iodine contrast agent raw materials and quinolone raw materials [1] - The revenue composition of the company includes: contrast agents 79.73%, other supplementary products 10.19%, other 6.16%, CMO/CDMO 2.41%, and quinolone series 1.52% [1] Group 2: Fund Holdings - One fund, Xingye Healthcare A (011466), holds a significant position in Sitaili, with 1.8991 million shares, accounting for 4.83% of the fund's net value, making it the sixth-largest holding [2] - The fund has achieved a year-to-date return of 36.14% and a one-year return of 49.23%, ranking 1872 out of 8246 and 3177 out of 8054 in its category, respectively [2] - The fund manager, Chen Xu, has been in position for 4 years and 193 days, with a total fund size of 385 million CNY [2]